Action Characteristics of Traditional Chinese Medicine in Treatment of Alzheimer's Disease

被引:9
|
作者
Li Lin [1 ]
Zhang Lan [1 ]
机构
[1] Capital Med Univ, Xuanwu Hosp, Dept Pharmacol, Key Lab Neurodegenerat Dis,Minist Educ, Beijing 100053, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Alzheimer's disease; therapeutics; traditional Chinese medicine; Shenwu capsule; Tetrahydroxy-stilbene glucoside; Cornel iridoid glycoside; Epimedium flavone; Icariin; animal model; cellular model; CORNEL IRIDOID GLYCOSIDE; TETRAHYDROXYSTILBENE-GLUCOSIDE; MEMORY ABILITIES; NERVE-CELLS; EXPRESSION; MODEL; PROGRESS; RATS; MICE;
D O I
10.3724/SP.J.1206.2012.00230
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) is a multifactorial complex disease. The failure of recent development of AD therapeutic agents in clinical trials is mainly due to their single-target or single-pathogenic pathway effect. The poor clinical outcome of AD treatment is also due to the late intervention. A large number of neuronal death has already happened at the time of diagnosis. Aiming at the complex diseases with unclear causes and many related factors, the multi-target and multi-link treatment characteristics of traditional Chinese medicine have advantages over the single target treatment. Therefore, we have committed to the research of traditional Chinese medicine in treatment of AD and the development of new drugs since 1995. In this paper, our research results for more than 10 years were reviewed. Our study showed that traditional Chinese medicine formula (Shenwu capsule) and single herb extracts (Tetrahydroxy-stilbene glucoside, Cornel iridoid glycoside, Epimedium flavone and Icariin) could act on the complex pathogenesis of AD at multi-targets and multi-pathways, especially have both neuroprotective and neurotrophic/regenerative effects, and protect mitochondria and synapses, thus have significant features and advantages for the treatment of AD.
引用
收藏
页码:816 / 828
页数:13
相关论文
共 111 条
  • [1] [Anonymous], CHIN J REHABILITATIO
  • [2] [Anonymous], 2004, CHINESE J CLIN REHAB
  • [3] Chen L. Z., 2004, CHIN J CLIN REHABILI, V8, P1912
  • [4] [陈莲珍 Chen Lianzhen], 2005, [中国药学杂志, Chinese Pharmaceutical Journal], V40, P1143
  • [5] [陈莲珍 Chen Lianzhen], 2005, [中国药学杂志, Chinese Pharmaceutical Journal], V40, P23
  • [6] Chu J., 2008, J U SCI TECHNOL CHIN, V38, P339
  • [7] Chu J., 2005, CHINA PHARM, V16, P13
  • [8] [楚晋 CHU Jin], 2008, [中华医学杂志, National Medical Journal of China], V88, P31
  • [9] [楚晋 Chu Jin], 2004, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V15, P235
  • [10] [楚晋 CHU Jin], 2006, [基础医学与临床, Basic Medical Sciences and Clinics], V26, P197